House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Gastroenterology

Ulcerative Colitis in Adults

ACG · 2025 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The ACG adult ulcerative-colitis guideline separates confirmation and monitoring, induction of remission, maintenance, and hospital management of acute severe colitis. Treatment follows inflammatory severity and prognosis as well as bowel extent, aiming for sustained steroid-free remission and endoscopic improvement.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Confirm disease and monitor meaningful targets

  • Suspect UC with rectal bleeding, increased stool frequency or urgency. Exclude infection, including stool testing for C. difficile. Confirm with ileocolonoscopy and biopsies of affected and unaffected mucosa; antibody serology should not establish or exclude UC or predict its prognosis. [1]
  • Grade disease using symptoms, endoscopic extent and severity, inflammatory markers, previous steroid or hospital needs, treatment response and impact on daily life. Record a validated endoscopic score; a short affected segment does not make severe inflammation mild. [1]
  • Aim for steroid-free remission with endoscopic improvement, defined here as Mayo endoscopic score 0 or 1. Use faecal calprotectin to assess response, suspected relapse and maintenance; histological remission is not yet a prospectively validated preferred treatment target. [1]

Induce and maintain remission in mild to moderate disease

  • For mildly to moderately active proctitis, use rectal 5-ASA 1 g daily for induction. Rectal 5-ASA enemas at least 1 g daily are preferred to rectal steroids for proctitis or left-sided disease; topical steroid or, after topical 5-ASA failure in proctitis, tacrolimus or beclomethasone suppositories are conditional alternatives. [1]
  • For mildly to moderately active left-sided UC, consider rectal 5-ASA at least 1 g daily plus oral 5-ASA at least 2 g daily rather than oral therapy alone. For extensive mild to moderate disease, oral 5-ASA at least 2 g daily is recommended. [1]
  • For left-sided disease intolerant or unresponsive to adequately dosed oral and rectal 5-ASA, use budesonide MMX 9 mg daily for induction. Adding that dose is also recommended for mild to moderate UC of any extent unresponsive to oral 5-ASA. [1]
  • If appropriate 5-ASA fails, escalate to another therapeutic class rather than repeatedly changing the 5-ASA formulation; systemic oral corticosteroids are an induction option. Reassess mild to moderate disease within 8 weeks, and use moderate-to-severe treatment strategies when adverse prognostic factors warrant it. [1]
  • Maintain remission with rectal 5-ASA 1 g daily after mild proctitis, or oral 5-ASA at least 1.5 g daily after mild left-sided or extensive disease. Do not use systemic, rectal or budesonide MMX corticosteroids as maintenance. [1]

Select advanced treatment and plan maintenance

  • Moderately to severely active disease may require systemic corticosteroid induction or an effective advanced induction strategy. Thiopurine or methotrexate monotherapy should not be used for induction. Severe isolated proctitis also warrants access to advanced treatment suited to its activity. [1]
  • Recommended induction options for moderate to severe UC include ozanimod or etrasimod, ustekinumab, and the IL-23 inhibitors guselkumab, mirikizumab or risankizumab. These are alternative strategies selected for the individual, not a combination regimen. [1]
  • For moderately to severely active UC, vedolizumab, anti-TNF treatment and the JAK inhibitors tofacitinib or upadacitinib are also recommended induction options. Infliximab is the preferred anti-TNF; the guideline recommends vedolizumab over adalimumab for induction and maintenance. [1]
  • When inducing remission with infliximab in moderate to severe UC, combine with a thiopurine when appropriate; the recommendation has evidence for azathioprine. Do not generalize this combination evidence to every biologic or immunomodulator. [1]
  • After remission of previously moderately to severely active UC, usually continue the effective steroid-sparing induction agent for maintenance. After steroid-induced remission, thiopurine maintenance is a conditional option; systemic steroid maintenance is discouraged, and methotrexate maintenance is conditionally discouraged. [1]
  • For loss of anti-TNF response, consider drug levels and, if drug exposure is insufficient, anti-drug antibodies. Primary nonresponse despite adequate levels favours considering a different mechanism rather than another anti-TNF. Routine proactive monitoring of every patient in remission has insufficient supporting evidence. [1]
  • Account for infection risk and extraintestinal disease when selecting treatment. Seek surgical advice for moderate to severe UC refractory or intolerant to medical therapy; persistent loss of remission despite optimized treatment can justify elective proctocolectomy. [1]

Manage acute severe colitis in hospital

  • Acute severe UC requires hospital care, supportive fluids and electrolytes, and assessment for toxic megacolon. Test for C. difficile and perform flexible sigmoidoscopy within 72 hours, preferably within 24 hours, obtaining biopsies for CMV. [1]
  • Use pharmacological venous-thromboembolism prophylaxis in ASUC. Do not routinely use broad-spectrum antibiotics, and do not prescribe total parenteral nutrition merely to rest the bowel. [1]
  • Recommended intravenous steroid regimens for ASUC are methylprednisolone totaling 60 mg daily or hydrocortisone 100 mg three or four times daily. Assess stools, bleeding, examination, vital signs and serial CRP while treating. [1]
  • If response to intravenous steroids is inadequate by day 3, use infliximab or ciclosporin rescue and obtain surgical consultation; suspected toxicity also requires surgical review. Choice of rescue depends on expertise, prior treatment failures and serum albumin. [1]
  • Toxic megacolon, perforation, severe refractory bleeding or medical-treatment failure indicate surgery. Do not defer needed colectomy because infliximab or ciclosporin has been given. Avoid NSAIDs, narcotics and medicines with anticholinergic effects in ASUC. [1]
  • After successful infliximab rescue for ASUC, continue infliximab maintenance. After ciclosporin rescue, thiopurines or vedolizumab are conditional maintenance options. Routine tofacitinib or upadacitinib rescue after steroid or infliximab failure is not supported by sufficient data in this guideline. [1]

Limitations and use

  • This summary draws on the formal recommendations and key concepts plus selected hospital-management context. It does not supply complete advanced-drug dosing, pretreatment infection screening, contraindications, pregnancy advice, colorectal-cancer surveillance or surgical procedures. Induction and maintenance options are alternatives whose suitability and safety require the full guideline, current medicine information and individual assessment.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Ulcerative Colitis in Adults

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
ACG
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Confirm disease and monitor meaningful targets
  • Induce and maintain remission in mild to moderate disease
  • Select advanced treatment and plan maintenance
  • Manage acute severe colitis in hospital
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House